<DOC>
	<DOCNO>NCT02508298</DOCNO>
	<brief_summary>This prospective longitudinal study evaluate change ( pre post therapy ) indocyanine green ( ICG ) retention test liver stiff ness ( LS ) spleen stiffness ( SS ) measure acoustic radiofrequency impulse ( ARFI ) correlate change portal pressure determine hepatic vein pressure gradient ( HVPG ) patient compensate hepatitis C virus ( HCV ) cirrhosis undergo antiviral therapy .</brief_summary>
	<brief_title>Surrogate Markers Portal Pressure</brief_title>
	<detailed_description>Subjects recruit outpatient set West Haven VA Medical Center Yale Liver Clinic . Subjects 18-85 year age compensate cirrhosis due chronic hepatitis C virus ( HCV ) infection start anti-viral therapy treat HCV within next 3 month eligible study . 33 subject ( assume 10 % loss follow-up ) recruit participation last 6-12 month . The expected duration study 2 year . The primary end point study correlate change ( baseline complete anti-HCV therapy ) ICG retention test , LS SS measure ARFI HVPG . After consent obtain , subject undergo ICG retention test , ARFI image HVPG measurement HCV therapy . Blood sample , demographic clinical data collect HCV therapy . Correlations change HVPG change ICG , LS SS assess . With 30 patient , 80 % power perform hypothesis test Pearson correlation assume observed correlation 0.70 two-sided type I error rate 0.05 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<criteria>Age 1885 HCV infection ( HCVRNA positive ) Compensated cirrhosis define histologically and/or clinically ( presence compatible lab finding ( platelet count ≤ 150,000 , total bilirubin ≥ 2 , serum albumin ≤ 3.5 , INR ≥ 1.2 ) PLUS compatible physical exam feature ( cutaneous stigma , gynecomastia men , splenomegaly ) OR compatible radiological finding ( nodular liver surface , splenomegaly , and/or collateral ) . ( The ultimate confirmation diagnosis cirrhosis baseline HVPG &gt; 5 mmHg ) Planned antiHCV therapy next 3 month Any clinicallyevident complication cirrhosis define decompensation : jaundice , ascites , variceal hemorrhage , overt hepatic encephalopathy ) Hepatocellular carcinoma Coinfection HBV HIV Ongoing alcohol abuse Occlusive portal thrombosis , Presence comorbid condition confer life expectancy &lt; 1 year , history allergy iodide , pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ICG</keyword>
	<keyword>ARFI</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>diagnostic study</keyword>
</DOC>